kneat.com (TSE:KSI) Sets New 12-Month High – Should You Buy?

kneat.com, inc. (TSE:KSI)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as C$6.65 and last traded at C$6.65, with a volume of 40992 shares trading hands. The stock had previously closed at C$6.35.

Wall Street Analyst Weigh In

Several research analysts have commented on KSI shares. Cibc World Mkts upgraded shares of kneat.com to a “strong-buy” rating in a report on Tuesday, October 29th. CIBC set a C$6.00 target price on kneat.com and gave the company an “outperform” rating in a report on Tuesday, October 29th.

kneat.com Stock Performance

The stock has a market cap of C$584.80 million, a PE ratio of -42.50, a PEG ratio of 597.67 and a beta of 1.08. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50. The firm has a 50 day moving average of C$6.01 and a two-hundred day moving average of C$5.17.

kneat.com (TSE:KSI) last issued its earnings results on Wednesday, November 6th. The company reported C$0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.05) by C$0.06. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%. During the same period in the previous year, the business posted ($0.05) earnings per share. Research analysts predict that kneat.com, inc. will post -0.12 EPS for the current fiscal year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.